Palvella Therapeutics Files 8-K on Financials
Ticker: PVLA · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1583648
| Field | Detail |
|---|---|
| Company | Palvella Therapeutics, Inc. (PVLA) |
| Form Type | 8-K |
| Filed Date | Nov 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, corporate-actions
Related Tickers: PVLA
TL;DR
Palvella Therapeutics (PVLA) filed an 8-K detailing financial results and other disclosures.
AI Summary
Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) filed an 8-K on November 10, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits. The company, incorporated in Nevada, is in the Pharmaceutical Preparations industry and is headquartered in Wayne, PA.
Why It Matters
This filing provides crucial updates on Palvella Therapeutics' financial health and operational status, which is important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting on financial condition and operations, not indicating any immediate or significant new risks.
Key Players & Entities
- PALVELLA THERAPEUTICS, INC. (company) — Registrant
- Pieris Pharmaceuticals, Inc. (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
- Wayne, PA (location) — Business address city and state
- November 10, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for Palvella Therapeutics?
The primary purpose is to report on the company's Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits.
What was Palvella Therapeutics' former name?
Palvella Therapeutics, Inc. was formerly known as Pieris Pharmaceuticals, Inc.
In which state is Palvella Therapeutics incorporated?
Palvella Therapeutics, Inc. is incorporated in Nevada.
What is the business address of Palvella Therapeutics?
The business address is 353 W. Lancaster Ave, Suite 200, Wayne, PA 19087.
What is the SIC code for Palvella Therapeutics?
The Standard Industrial Classification (SIC) code for Palvella Therapeutics is 2834, Pharmaceutical Preparations.
Filing Stats: 672 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-11-10 16:30:33
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PVLA The Nasdaq
Filing Documents
- pvla-20251110.htm (8-K) — 50KB
- pvla-ex99_1.htm (EX-99.1) — 181KB
- pvla-ex99_2.htm (EX-99.2) — 20KB
- img6060170_0.jpg (GRAPHIC) — 33KB
- img6060170_1.jpg (GRAPHIC) — 33KB
- img6060170_2.jpg (GRAPHIC) — 33KB
- pvla-ex99_2s1.jpg (GRAPHIC) — 247KB
- pvla-ex99_2s2.jpg (GRAPHIC) — 801KB
- pvla-ex99_2s3.jpg (GRAPHIC) — 325KB
- pvla-ex99_2s4.jpg (GRAPHIC) — 408KB
- pvla-ex99_2s5.jpg (GRAPHIC) — 396KB
- pvla-ex99_2s6.jpg (GRAPHIC) — 145KB
- pvla-ex99_2s7.jpg (GRAPHIC) — 356KB
- pvla-ex99_2s8.jpg (GRAPHIC) — 355KB
- pvla-ex99_2s9.jpg (GRAPHIC) — 374KB
- pvla-ex99_2s10.jpg (GRAPHIC) — 298KB
- pvla-ex99_2s11.jpg (GRAPHIC) — 139KB
- pvla-ex99_2s12.jpg (GRAPHIC) — 453KB
- pvla-ex99_2s13.jpg (GRAPHIC) — 383KB
- pvla-ex99_2s14.jpg (GRAPHIC) — 408KB
- pvla-ex99_2s15.jpg (GRAPHIC) — 388KB
- pvla-ex99_2s16.jpg (GRAPHIC) — 322KB
- pvla-ex99_2s17.jpg (GRAPHIC) — 125KB
- pvla-ex99_2s18.jpg (GRAPHIC) — 208KB
- pvla-ex99_2s19.jpg (GRAPHIC) — 141KB
- 0001193125-25-274378.txt ( ) — 9175KB
- pvla-20251110.xsd (EX-101.SCH) — 42KB
- pvla-20251110_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 11, 2025, Palvella Therapeutics, Inc. (the " Company ") expects to issue a press release announcing its financial results for the quarter ended September 30, 2025. In light of the U.S. national holiday on November 11, 2025, the Company is furnishing a copy of such press release as Exhibit 99.1 to this Current Report on Form 8-K and such press release is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 11, 2025, the Company expects to hold its earnings call and use a slide presentation in conjunction with the earnings call. A copy of the presentation is furnished herewith as Exhibit 99.2, and incorporated herein by reference. The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Palvella Therapeutics, Inc., dated November 11, 2025* 99.2 Earnings Call Presentation of Palvella Therapeutics, Inc., dated November 11, 2025* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Furnished herewith
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Palvella Therapeutics, Inc. Date: November 10, 2025 By: /s/ Matthew Korenberg Matthew Korenberg Chief Financial Officer